Cover Image
市場調查報告書

歐盟5國的MA (醫療事務) 部門的評估:腎細胞癌

Medical Affairs Reputations: Renal Cell Carcinoma (EU5)

出版商 FirstWord 商品編碼 358495
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
歐盟5國的MA (醫療事務) 部門的評估:腎細胞癌 Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
出版日期: 2016年04月01日 內容資訊: 英文
簡介

本報告以腎細胞癌治療藥的主要7個產品相關的醫療事務 (MA) 團隊上,歐盟5國的150名癌症專門醫生為對象加以調查,彙整其對各公司團隊的效能及滿意度評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析。

對象的企業·品牌

  • Afinitor (Everolimus:Novartis)
  • Avastin (Bevacizumab:Roche)
  • Inlyta (Axitinib :Pfizer)
  • Proleukin (Aldesleukin:Novartis)
  • Sutent (Sunitinib:Pfizer)
  • Torisel (temushirorimusu:Pfizer)
  • Votrient (Pazopanib:Novartis)

調查·分析內容範例

  • MA隊的利用方法·頻率
  • 一般認為最重要的服務
  • 聯繫的頻率和偏好的途徑
  • 醫生對各團隊的印象
  • 各隊伍的效能·滿意度排行榜:12項
  • 醫生的需求與服務的改善點
目錄
Product Code: 596200648

4 medical affairs teams working hard to engage oncologists. Which one gets top marks?

European medical affairs teams for four renal cell carcinoma (RCC) treatments have been working overtime, interacting with 12-58% more oncologists than any other team in the past 6 months.

Is all their hard work paying off?

Find out which team scores highest for overall quality, and how oncologists rate the medical affairs teams for 7 major RCC treatments in Medical Affairs Reputations: RCC.

You'll learn whether your team is giving oncologists the services they want, whether they're satisfied with your performance, and where you need the most improvement.

Answering Key Questions about Medical Affairs Teams for 8 Major RCC Brands

  • Afinitor (everolimus; Novartis): Which medical affairs team is more active, Afinitor's or Inlyta's?
  • Avastin (bevacizumab; Roche): Do oncologists think Avastin's team does a better job providing competitive information or information about clinical trials?
  • Inlyta (axitinib; Pfizer): Is Inlyta's team doing a better job of responding to inquiries or providing oncologists with relevant materials?
  • Proleukin (aldesleukin; Novartis): Proleukin's team gets high performance and satisfaction scores in most areas. How does it rank for overall quality of interactions?
  • Sutent (sunitinib; Pfizer): Sutent's team's satisfaction scores are far ahead of the pack in one key area. Which one?
  • Torisel (temsirolimus; Pfizer): Torisel's team has the lowest satisfaction scores in all but one area. Which one?
  • Votrient (pazopanib; Novartis): Which team ranks higher for overall quality of interactions, Votrient's or Sutent's?

Top Takeaways

  • Fierce competition at the top of the market: Rated for overall quality of interactions, less than 4 points separate the 1st place team from the 4th place team.
  • Top 4 teams are highly active: In the last 6 months, they had up to a little over three times as many interactions with oncologists as other teams surveyed.
  • Oncologists hungry for information: They say the most important, and most used medical affairs services involve providing information and clinical support.
  • Oncologists prefer face to face: In-person interaction types rank higher than electronic interactions and phone calls, although email is fairly well tolerated.
  • Teams doing a relatively good job: Though not off the charts, performance scores for every team covered are at least moderately high-and highest in the areas important to oncologists.
  • Some areas need improvement: Of the five medical affairs services most important to oncologists, most teams need to improve satisfaction in two of them.
  • Satisfaction could be better: Several teams have average satisfaction scores in most areas. Surprisingly, some of the highest scores go to the team with the lowest overall quality rating.
  • Time to get organized: Several oncologists suggested improved organization and appointment scheduling as a way for medical affairs teams to provide better services.

An Expert-designed Competitive View of Your Medical Affairs Team

Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 8 medical affairs teams-answering important questions like:

What do oncologists need?

  • How, and how often are they using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with oncologists?
  • How do oncologists rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to oncologists?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Interviews with Practicing Oncologists

We surveyed 100 US medical oncologists, chosen from the largest community of validated physicians in the world.

All respondents:

  • Have been practicing for between 3 and 35 years
  • See at least 5 patients with NSCLC in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted with at least one listed product's medical affairs team in the last 6 months.

We conducted the survey between March 2nd and March 17th, 2016.

Back to Top